https://scholars.lib.ntu.edu.tw/handle/123456789/634862
標題: | Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials | 作者: | MEI-JYH CHEN Chen, Po-Yueh YU-JEN FANG Bair, Ming-Jong CHIEH-CHANG CHEN CHIEN-CHUAN CHEN Yang, Tsung-Hua Lee, Ji-Yuh Yu, Chien-Chun Kuo, Chia-Chi Chiu, Min-Chin Chou, Chu-Kuang Chen, Chi-Yi Hu, Wen-Hao Tsai, Min-Horn Hsu, Yao-Chun CHIA-TUNG SHUN Luo, Jiing-Chyuan JAW-TOWN LIN El-Omar, Emad M MING-SHIANG WU JYH-MING LIOU |
公開日期: | 七月-2023 | 卷: | 8 | 期: | 7 | 起(迄)頁: | 632 | 來源出版物: | The lancet. Gastroenterology & hepatology | 摘要: | Helicobacter pylori infection is an important causal factor of gastric cancer and peptic ulcer disease and is associated with immune thrombocytopenic purpura and functional dyspepsia. In H pylori strains, point mutations in the 23S rRNA and gyrA genes are associated with clarithromycin resistance and levofloxacin resistance, respectively. Whether the efficacy of molecular testing-guided therapy is non-inferior to that of susceptibility testing-guided therapy for H pylori eradication is unclear. Therefore, we aimed to compare the efficacy and safety of molecular testing-guided therapy and traditional culture-based susceptibility testing-guided therapy in first-line and third-line treatment of H pylori infection. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85161040244&origin=resultslist&sort=plf-f https://scholars.lib.ntu.edu.tw/handle/123456789/634862 |
ISSN: | 24681253 | DOI: | 10.1016/S2468-1253(23)00097-3 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。